GlassScriptPhysician profile
Carole C Howard
NPI 1447234885
$652.99
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $88.78 · 2021: $237 · 2022: $132.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $134.25 | 2019-2022 | |
| Novo Nordisk INC | $98.96 | 2019-2021 | |
| Abbvie INC. | $84.31 | 2021-2022 | |
| Lilly USA, LLC | $52.43 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $47.45 | 2021-2022 | |
| Pfizer INC. | $38.03 | 2019 | |
| Supernus Pharmaceuticals, INC. | $35.72 | 2022 | |
| Glaxosmithkline, LLC. | $30.27 | 2020-2022 | |
| Shire North American Group INC | $26.51 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $23.34 | 2021 | |
| Sanofi Pasteur INC. | $22.20 | 2021 | |
| Biofire Diagnostics, LLC | $18.26 | 2019 | |
| Nevro Corp. | $16.09 | 2019 | |
| Alk-Abello, INC | $12.60 | 2019 | |
| Amgen INC. | $12.57 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carole Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.